Advertisement

Topics

Eisai Signs Agreement With Merck & Co., Inc. to Expand Enrollment of Study for Halaven (Eribulin) and Pembrolizumab Combination Due to Encouraging Initial Data in Triple-Negative Breast Cancer

05:28 EDT 6 Sep 2017 | FinanzNachrichten

TOKYO, Sept 6, 2017 - (JCN Newswire) - Eisai Co., Ltd. has announced that it has signed an agreement with Merck & Co., Inc., Kenilworth, NJ, U.S.A. (known as MSD outside of the United States and Ca...

Original Article: Eisai Signs Agreement With Merck & Co., Inc. to Expand Enrollment of Study for Halaven (Eribulin) and Pembrolizumab Combination Due to Encouraging Initial Data in Triple-Negative Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "Eisai Signs Agreement With Merck & Co., Inc. to Expand Enrollment of Study for Halaven (Eribulin) and Pembrolizumab Combination Due to Encouraging Initial Data in Triple-Negative Breast Cancer"

Quick Search
Advertisement
 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...